Tamara Rushovich

Ms. Tamara Rushovich


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Social Science & Medicine
Verified
Journal Article
Closed access
ADAnn Caroline Caroline Danielsen
Ann Caroline Caroline Danielsen
KLKatharine Mn Lee
Katharine Mn Lee
MBMarion Boulicault
Marion Boulicault
TRTamara Rushovich
Tamara Rushovich
AGAnnika Gompers
Annika Gompers
SRSarah S. Richardson
Sarah S. Richardson

5 April 2021 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
TRTamara Rushovich
Tamara Rushovich
MBMarion Boulicault
Marion Boulicault
JCJarvis T. Chen
Jarvis T. Chen
ADAnn Caroline Danielsen
Ann Caroline Danielsen
ATAmelia Tarrant
Amelia Tarrant
HSHeather Shattuck-Heidorn
Heather Shattuck-Heidorn

8 November 2023 in Social Science & Medicine
Verified
Journal Article
Open access
KLKatharine M.N. Lee
Katharine M.N. Lee
TRTamara Rushovich
Tamara Rushovich
AGAnnika Gompers
Annika Gompers
MBMarion Boulicault
Marion Boulicault
SWSteven Worthington
Steven Worthington
SRSarah S. Richardson
Sarah S. Richardson
Pharmacovigilance databases contain larger numbers of adverse drug events (ADEs) that occurred in women compared to men. The cause of this disparity is frequently attributed to sex-linked biological factors. We offer an alternative Gender Hypothesis, positing that gendered social factors are central to the production of aggregate sex disparities in ADE reports. We describe four pathways through which gender may influence observed sex disparities in pharmacovigilance databases: healthcare utilization; bias and discrimination in the clinic; experience of a drug event as adverse; and pre-existing social and structural determinants of health. We then use data from the U.S. FDA Adverse Event Reporting System (FAERS) to explore how the Gender Hypothesis might generate novel predictions and explanations of sex disparities in ADEs in existing widely referenced datasets. Analyzing more than 37 million records of ADEs between 2014 and 2022, we find that patient-reported ADEs show a larger female skew than healthcare provider-reported ADEs and that the sex disparity is markedly smaller for outcomes involving death or hospitalization. We also find that the sex disparity varies greatly across types of ADEs, for example, cosmetically salient ADEs are skewed heavily female and sexual dysfunction ADEs are skewed male. Together, we interpret these findings as providing evidence of the promise of the Gender Hypothesis for identifying intervenable mechanisms and pathways contributing to sex disparities in ADEs. Rigorous application of the Gender Hypothesis to additional datasets and in future research studies could yield new insights into the causes of sex disparities in ADEs.

1 August 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
TRTamara Rushovich
Tamara Rushovich
AGAnnika Gompers
Annika Gompers
JLJeffrey W. Lockhart
Jeffrey W. Lockhart
IOIfe Omidiran
Ife Omidiran
SWSteven Worthington
Steven Worthington
KLKatharine M. N. Lee
Katharine M. N. Lee
Although they have known limitations,1 spontaneous reporting pharmacovigilance databases like the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and World Health Organization VigiBase are widely cited as evidence for claims that women experience adverse drug events (ADEs) at as high as twice the rate of men.2,3 Pharmacokinetics and pharmacodynamics are typically used to explain these sex differences2; however, many factors could influence the distribution of ADE reports by sex, including well-known disparities in the rates at which men and women use prescribed drugs.4 This study examined ADEs reported by sex in the FAERS database after adjusting for drug use by men and women. Information regarding how sex and gender are conceptualized in this study and its data sources appears in Supplement 1.

28 January 2020 in Journal of Ethnicity in Substance Abuse
Verified
Journal Article
Closed access
TRTamara Rushovich
Tamara Rushovich
MAM. Allison Arwady
M. Allison Arwady
ESElizabeth Salisbury-Afshar
Elizabeth Salisbury-Afshar
PAPonni Arunkumar
Ponni Arunkumar
SASteven Aks
Steven Aks
NPNikhil Prachand
Nikhil Prachand
Compared to national findings, Chicago has both a higher rate of opioid-related overdose death and a markedly different distribution by demographics. The Chicago Department of Public Health analyzed fatal overdoses by level of neighborhood economic hardship. The highest rate of opioid-related deaths occurred in neighborhoods with high economic hardship (36.9 per 100,000 population) compared to medium- (20.5) and low- (12.3) hardship neighborhoods. However, these patterns were not consistent across racial/Hispanic ethnicity subgroups. These data support the need to consider the role of racism and other structural, social, and economic factors when designing interventions to reduce opioid-related overdose deaths.

1 March 2024 in American Journal of Public Health
Verified
Journal Article
Closed access
TRTamara Rushovich
Tamara Rushovich
RNRachel C. Nethery
Rachel C. Nethery
AWAriel White
Ariel White
NKNancy Krieger
Nancy Krieger
Objectives. To investigate the impact of the US Voting Rights Act (VRA) of 1965 on Black and Black versus White infant deaths in Jim Crow states. Methods. Using data from 1959 to 1980 and 2017 to 2021, we applied difference-in-differences methods to quantify differential pre–post VRA changes in infant deaths in VRA-exposed versus unexposed counties, controlling for population size and social, economic, and health system characteristics. VRA-exposed counties, identified by Section 4, were subject to government interventions to remove existing racist voter suppression policies. Results. Black infant deaths in VRA-exposed counties decreased by an average of 11.4 (95% confidence interval [CI] = 1.7, 21.0) additional deaths beyond the decrease experienced by unexposed counties between the pre-VRA period (1959–1965) and the post-VRA period (1966–1970). This translates to 6703 (95% CI = 999.6, 12 348) or 17.5% (95% CI = 3.1%, 28.1%) fewer deaths than would have been experienced in the absence of the VRA. The equivalent differential changes were not significant among the White or total population. Conclusions. Passage of the VRA led to pronounced reductions in Black infant deaths in Southern counties subject to government intervention because these counties had particularly egregious voter suppression practices. ( Am J Public Health. 2024;114(3):300–308. https://doi.org/10.2105/AJPH.2023.307518 )